Top 10 most read articles of the year 2022
Pan-European disputes once again piqued JUVE Patent readers' interest over 2022, with this year's top ten most-read articles leading with the case between Sandoz, Teva and Novartis over apixaban. Medical devices also came to the fore in the multi-patent action between Dexcom and Abbott, while Munich Regional Court's approach to connected cars and FRAND got the market talking. However, Nokia against Oppo is by the far the most popular case for JUVE Patent's readers over 2022 – not forgetting further changes at the EPO, as well as the market closely following more developments at the UPC.
27 December 2022 by Amy Sandys
JUVE Patent rounds up its top ten most-read articles of 2022 ©SFIO CRACHO/ADOBE STOCK
These are the ten most-read articles by JUVE Patent readers in 2022:
1. Sandoz and Teva invalidate blockbuster apixaban patent and SPC
2. Nokia and Bird & Bird win against Oppo over wifi connection patent
3. Dissatisfied industry users push back against EPO quality measures
4. Nokia prevails against Oppo as court rules on SEP infringement
5. UPC Administrative Committee publishes final judges list
6. Nokia and Oppo battle in full swing following UK Supreme Court ruling
7. Munich Regional Court takes new approach to FRAND
8. Moderna sues Pfizer and BioNTech with Freshfields in Europe
9. Dexcom and Abbott’s fight over glucose monitoring patents intensifies in Europe
10. Brinkhof and Vossius shake up UPC with new brand offering
